BPC-157 vs Thymosin Beta-4
A side-by-side research comparison of BPC-157 and Thymosin Beta-4 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | BPC-157 | Thymosin Beta-4 |
|---|---|---|
| Full name | Body Protection Compound-157 | Thymosin Beta-4 (Full Length) |
| Category | Healing & Recovery | Healing & Recovery |
| Status | Research compound | Research compound |
| Mechanism | Upregulates growth factor expression including VEGF and promotes angiogenesis, modulates nitric oxide system, and interacts with the dopaminergic system. | Sequesters G-actin to regulate cytoskeleton dynamics, promotes stem cell differentiation, and activates anti-inflammatory and anti-apoptotic pathways. |
| Molecular weight | 1419.53 Da | 4921 Da |
| Half-life | ~4 hours | ~6-8 hours |
| Bioavailability | Variable; oral and injectable forms available | ~95% subcutaneous |
| Typical dose | 250-500 mcg per dose | 1-5 mg |
| Frequency | 1-2x daily | 2-3x per week |
| Route | Subcutaneous injection (or oral capsules) | Subcutaneous injection |
BPC-157 reported benefits
- Accelerated tendon and ligament healing
- Gut lining protection and repair
- Neuroprotective effects
- Anti-inflammatory properties
- Muscle tear recovery
Thymosin Beta-4 reported benefits
- Comprehensive tissue repair
- Cardiac regeneration
- Neurological recovery
- Corneal healing
- Anti-fibrotic effects
Related comparisons
Research and educational reference only. Not medical advice.